Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Predictors of Intravenous Ketamine Response in Treatment-Resistant Depression
NCT05625555Phase 3Active, not recruiting
- Start
- Jan 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ketamine in treatment-resistant depression (TRD). Started Jan 2024; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05625555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625555.